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Objectives: To evaluate the clinical effects of blood puriﬁcation for treating fulminant hepatic
failure  (FHF).
Methods: Thirty-three severe FHF patients with hepatic encephalopathy (HE) above grade III
were subjected to a combined blood puriﬁcation treatment in addition to the comprehensive
liver  protection therapy. Patients underwent continuous hemoﬁltration on a daily basis dur-
ing the daytime followed by sequential treatment with plasma exchange or hemodialysis
every  2–3 days. The therapeutic effects of this treatment were evaluated.
Results:  After treatment with blood puriﬁcation, restoration of consciousness (those who
abandoned  the treatment without restoration of consciousness were excluded) was
achieved  in 6 of 8 cases (75%) in acute liver failure (ALF) group, 3 of 3 cases (100%) in subacute
liver  failure (SALF) group, and 9 of 14 cases (64.29%) in acute/subacute on chronic liver fail-
ure  (A/SCLF) group. Of all cases, 11 patients restored consciousness after 7 days in a coma.
The  rate of long-term survival (those who abandoned the treatment were  excluded) was  3/7
(42.86%) for ALF group, 2/2 (100%) for SALF group, and 1/11 (9.09%) for A/SCLF group. The
levels of hemoglobin and platelet in peripheral blood were signiﬁcantly reduced after blood
puriﬁcation.
Conclusions:  Treatment of FHF patients with daily continuous hemoﬁltration during the day-
time is effective in treating HE and in improving health status in the early stages of the
disease.  Long-term prognosis also beneﬁts from this treatment. The rate of consciousnessrecovery  and long-term survival is highest in SALF group followed by ALF group. This treat-
ment  is less effective in A/SCLF patients. It should be noted that blood puriﬁcation procedure
may  cause damage to blood cells.
severe  damage to liver function, patients with FHF develop
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© 20n clinical practice, fulminant hepatic failure (FHF) begins with
cute  liver failure, subacute liver failure, or acute/subacute on
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hepatic  encephalopathy above grade II in early stages. The
illness  progresses rapidly, and patients usually die from mul-
tiple  organ failure if immediate and effective treatment is not
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available. In this study, we treated FHF patients with daily
continuous hemoﬁltration, followed by sequential plasma
exchange  or hemodialysis every 2–3 days in addition to a
comprehensive liver protection therapy, and achieved positive
outcomes.
Subjects  and  methods
Subjects
Thirty-three FHF patients with HF above grade III in early
stages  were  recruited for this study. These patients were
admitted  to the hospital from October 2006 to May 2011. This
study  was  conducted in accordance with the declaration of
Helsinki  and approved by the Ethics Committee of No. 5 Peo-
ple’s  Hospital of Wuxi. Written informed consent was  obtained
from  all participants. According to the diagnostic standards
described in the “Diagnostic and treatment guidelines for liver
failure”1 (by the Chinese Society of Infectious Diseases and
Chinese  Society of Hepatology, Chinese Medical Association),
8  patients were diagnosed with ALF, 5 with SALF, and 20 with
A/SCLF.  There were  29 patients with hepatitis B virus infec-
tion,  1 with Hepatitis E virus infection, and 3 patients with
unknown etiology; 18 were male and 15 female; age ranged
from  23 to 65.
Methods
When symptoms of HE appeared, the patients were  treated
with  blood puriﬁcation as soon as possible until the restora-
tion  of consciousness. The modes of blood puriﬁcation used
in  this study were  as follows:
Daily  continuous hemoﬁltration: YF-70PAN membrane (area
0.7  m2) was  used as a hemoﬁlter. Port solution2 was  used
as  replacement ﬂuids. The concentration of KCl in the
replacement ﬂuids was  adjusted according to blood potas-
sium  concentration. All solutions except for bicarbonate were
loaded  into the infusion bag, and transferred in synchrony.
The  replacement ﬂuids were  transferred by a pre-dilution
method. Blood ﬂow rate was  150–200 ml/min. For anticoag-
ulation, an initial dose of 2000–4000 U low-molecular-weight
heparins was  used, followed by 4–20 U/min standard hep-
arin.  The additional heparins were omitted for those who had
severe  bleeding. In case of fever, the temperature of blood
replacement ﬂuids was  adjusted to around 35 ◦C. The volume
of  ultraﬁltrate was  determined by the condition of chemo-
sis  and other clinical features of the patients. The treatment
lasted  for 6–8 h each day.
Plasma exchange: IQ blood puriﬁcation instrument and
MicroPES plasmacureunit were  used for plasma exchange. The
total  volume of plasma exchanged was  1800–2400 ml.  The rate
of  plasma separation was  30 ml/min. Fresh cold plasma of the
same  type was  used as the replacement ﬂuid.
Hemodialysis: MicroPES A2 plasmacureunit and YF-70PAN
plasmacureunit were  used. The volume for each exchange was
1600–2000  ml.  Port solution was  used for hemodialysis.
Continuous hemoﬁltration at daytime was  the main puriﬁ-
cation  method and administered daily. Every 2–3 days,
patients underwent sequential plasma exchange or hemodial- 1 3;1  7(4):427–430
ysis.  During blood puriﬁcation treatment, comprehensive liver
protection therapy was  performed to protect liver cells and
prevent  complications. Delivery of 200–400 ml  human serum
albumin  and/or fresh frozen plasma by an intravenous drip
was  given as support treatment. Patients with a positive hep-
atitis  B virus test were treated with antiviral therapy using
nucleotide analogs.
Statistical  analysis
The t test was  used to determine whether there was  a sig-
niﬁcant  difference between two group means. Differences of
enumeration  data were compared with 2 test. Statistical sig-
niﬁcance  was deﬁned by p < 0.05.
Results
Evaluation  of  liver  function  in  patients
The patients we analyzed had severe FHF. There was  seri-
ous  damage to the liver function. Prothrombin activity in all
patients  was less than 30%, and even less than 10% in some
cases.  According to the clinical outcome after blood puriﬁ-
cation  treatment, patients were divided into three groups:
recovery  group (discharged from hospital with liver func-
tion  restored to normal), death group (died in hospital), and
abandoned  group (abandoned treatment and discharged from
hospital with no signiﬁcant improvement in liver function).
As  shown in Table 1, only total cholesterol level in abandoned
group  was  lower than in recovery and death groups. There
was  no signiﬁcant difference in other indexes, suggesting that
liver  function in all patients was  comparable at the time of
admission  to the hospital.
The  clinical  outcome  after  blood  puriﬁcation
After blood puriﬁcation, signiﬁcant improvement was
achieved and consciousness was completely restored in
18  FHF patients with HE. However, some patients despite
improving eventually died. The clinical outcome of blood
puriﬁcation in treatment of severe FHF is shown in Table 2.
The  rate of consciousness recovery (patients who  aban-
doned  treatment while still in a coma were  excluded) in all
patients  was  72% (18/25). It was  75% in ALF group, 100% in
SALF  group, and 64.29% in A/SCLF group. The recovery rate
in  A/SCLF group was  much  lower than that in ALF and SALF
groups  (p < 0.01). Long-term survival rate calculated according
to  the number of patients who were discharged from the
hospital  with restored liver function (those who  abandoned
treatment were excluded) was  42.86% in ALF group, 100% in
SALF  group, and 9.09% in A/SCLF group. The survival rate
in  A/SCLF group was  much  lower than that in ALF and SALF
groups  (p < 0.05).
Hospitalization  and  blood  puriﬁcation  of  the  recruited
patients
Among the 33 patients with severe FHF, 11 suffered from
HE  for 7 days. Of patients who died after restoration of
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Table 1 – Liver function before blood puriﬁcation (x ± s).
Group Case ALT (U/L) TBil (mol/L) Alb (U/L) Total cholesterol (mg/L) PT (S)
Recovery 6 1654.83 ± 1471.46 285.50 ± 104.71 34.35 ± 5.51 2.78 ± 0.87 62.92 ± 24.01
Death 14 1276.36 ± 652.24 296.71 ± 111.59 34.39 ± 4.81 2.56 ± 0.88 60.73 ± 29.15
Abandoned 13 919.25 ± 829.51 436.39 ± 169.37 35.13 ± 2.93 1.92 ± 0.43* 63.57 ± 16.83
∗ Compared to the recovery group p < 0.01.
Table 2 – Clinical outcome of patients treated with blood puriﬁcation.
Group Total number
(case)
ALF (case) SALF (case) A/SCLF (case)
Improved Not improved Improved Not improved Improved Not improved
Recovery 6 3 2 1
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onsciousness, 3 received blood puriﬁcation for more  than 10
imes  and 4 survived for more  than 30 days.
omparison  of  peripheral  blood  cells  before  and  after  blood
uriﬁcation in  patients  who  restored  consciousness
able 3 showed that the levels of hemoglobin and platelet were
arkedly reduced in either recovery group or death group
fter  blood puriﬁcation. The amount of platelets was already
uch  lower in death group before treatment. The amount of
emoglobin  was  decreased more  prominently in death group
han  recovery group after treatment.
omplications  associated  with  blood  puriﬁcation
hree patients had severe hematoma resulting from local
amage  caused by venipuncture. Of these patients, two were
n  death group. One died without restoration of consciousness.
iscussion
he mortality rate in FHF patients with HE is more  than 85%.3–5
mmediate and proper treatment of these patients is critical
o  achieve a successful salvage, which is worthy of further
nvestigation.
In  FHF patients, HF occurs rapidly. Encephaledema is
he  main cause for HE6 and is also a major determinant
or survival. When patients are suffering from liver failure,
etabolism slows down, and blood ammonia and other toxi-
ants  accumulate in the body. It is reported that the mortality
ate  of encephaledema or cerebral hernia in ALF patients is
orrelated  with the levels of artery blood ammonia.7 Patients
ith  liver failure are also accompanied by severe infection.
nfection and its induced inﬂammatory mediators such as
NF-,  IL-1, and IL-6 enhance the disturbance caused by high
lood  ammonia.8
Electrolyte and acid–base balances in patients with HE
re  often disturbed,9 which complicates the disease. There-
ore,  disturbance of internal environment occurs in patients
ith  severe FHF. It is important to improve the internal envi-
onment.  Continuous hemoﬁltration is the most effective
reatment to achieve rapid improvement of the disturbance5 5
2 3 6
of  internal environment. On one hand, it can eliminate blood
ammonia,  inﬂammatory factors, and other toxic substances,10
in addition to restoring the function of damaged endothelial
cells  in patients with pyaemia to alleviate the severity of the ill-
ness, and maintain water electrolyte and acid–base balance.11
On the other hand, it can also relieve encephaledema and
stabilize  the internal environment of patients.11
FHF patients with severe HE above grade III underwent
sequential plasma exchange or hemodialysis every 2–3 days
in  addition to routine continuous hemoﬁltration performed
on  daytime for 6–8 h to eliminate macromolecular protein-
binding toxins and to supplement bioactive substances that
the  body needs such as blood coagulation factors. The use
of  continuous hemoﬁltration at daytime instead of discon-
tinuous  hemoﬁltration for 24 h has several advantages. It
can  effectively eliminate toxic substances and meanwhile
reduce the loss of therapeutic drugs that have protective
effects on cell membranes, promoting liver cell growth, and
anti-infection. This mode of treatment also helps patients
to  change body position and to prevent the corresponding
complications. This combined method of blood puriﬁcation
signiﬁcantly improved the clinical outcome of FHF patients
and  achieved in a 72% restoration of consciousness in patients
with  grade III or IV severe HE. This suggested a good life-
supporting effect and fairly high rate of successful salvage.
We  observed that FHF patients with severe HE were  often in a
coma for a long time. Among them 61.11% were  in a coma
for  7 days. However, these patients restored consciousness
through the combined blood puriﬁcation. Thus, the time for
treatment  and persistence on the use of daily blood puriﬁca-
tion  until recovery are critical. We  also found that treatment
with  blood puriﬁcation for more  than 10 times had no appar-
ent  effects on the improvement of long-term prognosis.
After treatment with the combined blood puriﬁcation
therapy, 6 patients fully restored liver function and dis-
charged  from hospital, suggesting that this treatment not
only  extends life, but also promotes the survival of FHF
patients. The mortality rate of these patients is less than that
reported  in literature.We  observed that the rate of consciousness recovery and
long-term  survival after the combined blood puriﬁcation ther-
apy  was  highest in SALF group followed by ALF group. It
was  much  lower in A/SCLF group compared to the other
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Table 3 – Results of standard test for peripheral blood cells before and after blood puriﬁcation (x ± s).
Group Before treatment After treatment
WBC (×109/L) Hb (g/L) PLT (×109/L) WBC (×109/L) Hb (g/L) PLT (×109/L)
 42.9
 39.4
r
1
Chin Crit Care Med. 2003;15:109–13.
11.  Davenport A. Is there a role for continuous renal replacement
therapies in patients with liver and renal failure? Kidney IntRecovery 12.52 ± 4.38 134.00 ± 20.02 146.83 ±
Death 8.16 ± 2.81 124.14 ± 19.13 92.86 ±
two groups. In patients who died after restoration of con-
sciousness, four of them survived for more  than 30 days.
Furthermore, additional treatment did not improve the prog-
nosis  of these patients. The amount of platelet in these
patients was  less than that in those who completely recov-
ered  and were  discharged from hospital. Furthermore, after
the  treatment reduction in the level of hemoglobin was  also
more  signiﬁcant in death group than recovery group. These
results  indicate that the clinical outcome in patients treated
with  the combined blood puriﬁcation is inﬂuenced by the con-
dition  of liver function, technique of the treatment, and the
management  of complications.
We  found that the levels of hemoglobin and platelet were
signiﬁcantly decreased in both recovery group and death
group  after blood puriﬁcation, suggesting that this treat-
ment  can cause mechanical damage to peripheral blood cells.
Three  patients had severe hematoma resulting from local
damage  caused by venipuncture. Therefore, it is important to
reduce side effects during treatment.
In summary, continuous hemoﬁltration on a daily basis
during  daytime combined with sequentially treatment with
plasma  exchange or hemodialysis every 2–3 days are effective
in  treating patients with FHF.
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